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Abstract
Aim: Intravenous iron is increasingly used prior to surgery for colorectal cancer (CRC) to correct iron deficiency
anaemia and reduce blood transfusion. Its utility in functional iron deficiency (FID) or anaemia of inflammation is
less clear. This observational study examined post-iron infusion changes in haemoglobin (Hb) based on grouping
by C-reactive protein (CRP) and ferritin.
Methods: Anaemic (M:Hb < 130 mg/L, F:Hb < 120 mg/L) patients with CRC receiving iron infusion, within a
preoperative anaemia detection and correction protocol, at a single centre between 2016 and 2019 were included.
Patients were grouped by iron deficiency (ferritin < 30 μg/L and CRP ≤ 5 mg/L, n = 18), FID (ferritin < 30 μg/L and
CRP > 5 mg/L, n = 17), anaemia of inflammation (ferritin ≥ 30 μg/L and CRP > 5mg/L, n = 6), and anaemia of other
causes (ferritin ≥ 30 μg/L and CRP ≤ 5 mg/L, n = 6). Median change in Hb and postoperative day (POD) 1 Hb was
compared by Kruskal-Wallis test.
Results: Iron-deficient patients had the greatest increase in Hb after infusion (24 mg/L), highest POD 1 Hb (108 mg/
L), and required no blood transfusions. Patients with FID had the second greatest increase in Hb (15 mg/L) and
second highest POD 1 Hb (103 mg/L). Those with anaemia of inflammation had little increase in Hb after infusion
(3 mg/L) and lower POD 1 Hb (102 mg/L) than either iron-deficient group. Those without iron deficiency showed a
decrease in haemoglobin after infusion (− 5 mg/L) and lowest POD 1 Hb (95 mg/L).
Conclusions: Preoperative intravenous iron is less efficacious in patients with anaemia of inflammation and FID
undergoing surgery for CRC, compared with true iron deficiency. Further understanding of the role of perioperative
iron infusions is required for maximum gain from therapy.
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Introduction
Anaemia and perioperative allogeneic blood transfusion
are associated with poor outcomes following colorectal
cancer (CRC) surgery (Amato and Pescatori 2006). Peri-
operative optimisation of haemoglobin levels using iron
supplementation in iron-deficient patients has been shown
to reduce perioperative blood transfusion requirement in
colorectal surgery (Froessler et al. 2016). Furthermore,
parenteral iron infusions have been shown to improve
preoperative haemoglobin levels to a greater degree than
oral iron supplements (Keeler et al. 2017). As a result of
these observations, our specialist colorectal surgery unit
adopted preoperative iron deficiency anaemia identifica-
tion and iron infusion protocols in 2015 to optimise
patient haemoglobin prior to surgery (Quinn et al. 2017).
Although this form of optimisation targets those patients
with hypochromic microcytic anaemia of iron deficiency
classically associated with gastrointestinal cancers, there is
increasing evidence that normocytic anaemia is twice as
prevalent (around 20% at diagnosis, compared to 10% with
microcytic anaemia) amongst patients diagnosed with colo-
rectal cancer (McSorley et al. 2019a). Patients with normo-
cytic anaemia had higher levels of inflammation as
measured by modified Glasgow Prognostic Score (mGPS)
(McSorley et al. 2019b). Furthermore, such normocytic
anaemia was associated with poorer outcomes following
treatment with curative intent (Vayrynen et al. 2018).
It has been proposed that inflammation disturbs
hepcidin-mediated red cell iron binding and promotes a
‘functional’ iron deficiency (FID), where despite suffi-
cient stores, iron cannot be utilised for erythropoiesis,
leading to anaemia (Kelly et al. 2017). The same mecha-
nisms cause a reduction in enteral iron absorption and
sequestration of iron in the reticuloendothelial system,
leading to the possibility that any additional iron supple-
mentation given to these patients will not lead to a
corresponding change in haemoglobin concentration or
red cell count (Nemeth and Ganz 2014).
Therefore, the aim of the present study was to determine
if any patients with apparent anaemia of inflammation, or
FID, had been treated with preoperative parenteral iron
supplementation in our unit and, if so, to determine the im-
pact on haematological parameters. We hypothesised that
the presence of inflammation would perturb iron uptake by
cells and limit preoperative response to iron infusion. The
present study utilised a prospectively collected cohort of
primary colorectal cancer patients, given preoperative iron
infusions as determined by individual consultants in adher-
ence to unit protocol.
Patients and methods
Patients
Patients with primarily operable colorectal cancer receiv-
ing preoperative iron infusion followed by surgery in a
single centre between January 2016 and January 2019
were studied. Anonymised clinicopathological data were
prospectively recorded in a secure database and subse-
quently analysed. Patients undergoing surgery for benign
disease, with a diagnosed inflammatory disorder or
vasculitis, or an underlying haematological malignancy
were not included. Patient demographics, along with
TNM stage (TNM, 5th ed, AJCC), tumour site,
American Society of Anesthesiology (ASA) grade, and
surgical approach, were recorded.
All patients were treated by 11 consultant colorectal
surgeons in a single institution. All cases were discussed
at a specialist colorectal oncology multidisciplinary team
meeting, before and after surgery. Each patient was
cared for according to unit standardised ERAS protocols
and managed by a combination of laparoscopic or open
surgery dependent on surgeon preference. Treating sur-
geons were responsible for identification of anaemia in
their patients and determining whether this anaemia re-
quired treatment with iron infusion. Treating physicians
were encouraged to utilise protocols developed within
the unit by surgeons and anaesthetists (Fig. 1).
A waiver of need for ethical approval was granted by
the West of Scotland Research Ethics Committee. Caldi-
cott Guardian approval for the collection and analysis of
anonymised patient data as part of this project was
granted by the office of the Caldicott Guardian for the
NHS Greater Glasgow and Clyde region.
Methods
Haematological parameters—full blood count (FBC)-de-
rived haemoglobin and mean corpuscular volume
(MCV), ferritin, transferrin saturation (TSAT)—and the
biochemical inflammatory parameter C-reactive protein
were measured at the time of endoscopic diagnosis and
recorded prior to any subsequent parenteral iron infu-
sion, with the purpose of detecting iron deficiency an-
aemia. Patients were classified as having anaemia based
on WHO guidelines for males, haemoglobin (Hb) < 130
mg/L, and females, Hb < 120 mg/L (WHO 2011). Fur-
thermore, anaemic patients were classified as having iron
deficiency based on ferritin < 30 μg/L, ferritin 30–
100 μg/L with TSAT < 20% or CRP > 5mg/L, or ferritin
> 100 μg/L and transferrin saturation < 20% as shown
above (Fig. 1).
Serum concentrations of CRP (mg/L) were measured
by the immunoturbidimetric method in the clinical bio-
chemistry laboratory using an autoanalyser (Architect;
Abbot Diagnostics, Maidenhead, UK) with a lower de-
tectable limit of 0.2 mg/L. Ferritin was analysed using a
2-step chemiluminescent microparticle immunoassay in
the clinical haematology laboratory. There were no sus-
tained concerns regarding IQC performance requiring
investigation into the performance of the assays. The A,
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B, and C scores were within the EQA (UK NEQAS) tar-
gets during the study period.
Patients had FBC samples taken on the day of surgery
and again on postoperative day 1. The change in haemo-
globin following iron infusion was calculated by sub-
tracting immediate pre-operative haemoglobin from
haemoglobin at presentation.
Patients deemed suitable underwent administration of
intravenous ferric carboxymaltose (Ferinject®, Vifor
Pharma UK), via peripheral intravenous cannula over 15
min, in the preoperative assessment unit. The dose was
dependent on body weight and haemoglobin (Vifor
Pharma n.d.), and the aim was to have the first infusion
at least 14 days before surgery.
Statistical analysis
Patients were grouped by protocol-defined pre-infusion
ferritin and CRP cut-off values into those who were truly
iron deficient (ferritin < 30 μg/L and CRP ≤ 5 mg/L, n =
18), those with probable FID (ferritin < 30 μg/L and CRP
> 5mg/L, n = 17), those with probable anaemia of in-
flammation (ferritin ≥ 30 μg/L and CRP > 5mg/L, n =
6), and those with anaemia of another cause who were
given parenteral iron despite no evidence of iron
Fig. 1 Iron infusion pathway adopted in Glasgow Royal Infirmary. CNS, cancer nurse specialist; CRP, C-reactive protein; EPO, erythropoietin; FBC,
full blood count; FID, functional iron deficiency; GP, general practitioner; Hb, haemoglobin; IV, intravenous; T sat, transferrin saturation; SDAU,
same day admission unit
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deficiency (ferritin ≥ 30 μg/L and CRP ≤ 5 mg/L, n = 6).
Comparisons were made between categorical clinical
and pathological variables using the chi-square test and
chi-square test for trend where appropriate. Compari-
sons were made with pre-infusion haemoglobin, change
in haemoglobin, and postoperative day 1 haemoglobin
using the Kruskal-Wallis test.
Univariate linear regression was used to examine associ-
ations between these variables and change in haemoglobin
(Δ Hb mg/L) following iron infusion. Those variables
found to be associated with a significance level of p < 0.01
were entered into a multivariate linear regression back-
ward condition model to examine independent associ-
ation. Results were reported as the regression coefficient
for each variable and their 95% confidence interval (CI).
Two-sided p values < 0.05 were considered statistically
significant. All analyses were performed using IBM SPSS
version 25 (IBM, Chicago, Illinois, USA).
Results
Patients
Over the study period, 52 patients received an intraven-
ous iron infusion prior to elective surgery for colorectal
cancer. Patient demographics and clinical, pathological,
and haematological variables are shown in Table 1. The
majority were male (n = 30, 58%) and 65 years or older
(n = 43, 83%). Laparoscopic resection was performed in
27 (52%), and 45 (86%) had colonic cancer while the
remaining 7 (14%) had a rectal cancer. All patients were
anaemic prior to iron infusion, and of these, 49 had a
pre-infusion ferritin measured, 48 had a pre-infusion
CRP measured, and 47 had both measured. Thirty-six
(74%) had protocol defined low ferritin while half of the
48 patients who had CRP measured prior to iron infu-
sion had protocol defined systemic inflammation present
with a CRP > 5mg/L.
Iron infusion
The total dose of iron infused (Table 1) varied between
1000 mg (n = 19, 36%), 1500mg (n = 23, 45%), and
2000 mg (n = 11, 19%). The median time between infu-
sion and surgery was 24 days (range 1–83). Following
infusion, in the cohort as a whole, the median haemoglo-
bin change before surgery was a rise of 12 mg/L (range −
15 to 63), with haemoglobin rising above the cut-off for
anaemia in 8 patients (15%).
Associations between pre-iron infusion iron status and
clinicopathological variables
When patients were grouped by protocol-defined pre-
infusion ferritin and CRP cut-off values into those who
were truly iron deficient (ferritin < 30 μg/L and CRP ≤ 5
mg/L, n = 18), those with probable FID (ferritin < 30 μg/
L and CRP > 5mg/L, n = 17), those with probable
anaemia of inflammation (ferritin ≥ 30 μg/L and CRP >
5mg/L, n = 6), and those who were given parenteral iron
despite no evidence of iron deficiency (ferritin ≥ 30 μg/L
and CRP ≤ 5mg/L, n = 6), there was no association
between this pre-infusion iron status and sex, age, co-
morbidity, or disease stage (Table 2).
Only tumour site was significantly associated with pre-
infusion iron status (p = 0.006), with all of the rectal
cancer patients in the cohort (n = 7, 39% of all iron defi-
ciency patients) having true iron deficiency, while there
was a preponderance to right-sided lesions in the func-
tional iron deficiency (n = 17, 100%), anaemia of inflam-
mation (n = 5, 83%), and non-deficient (n = 5, 83%)
groups.
Associations between pre-infusion iron status and
haematological variables
Those patients (Table 2) who were categorised as truly
iron deficient (ferritin < 30 μg/L and CRP ≤ 5 mg/L, n =
18) had the lowest median pre-infusion haemoglobin
(100 mg/L, range 77 to 118). They had the greatest
median increase in haemoglobin between infusion and
surgery (24 mg/L, range − 6 to 48) and the highest me-
dian postoperative day 1 haemoglobin (108 mg/L, range
87 to 133).
Those patients who were categorised as FID (ferritin <
30 μg/L and CRP > 5mg/L, n = 17) had the second low-
est median pre-infusion haemoglobin (102mg/L, range
65 to 122), the second greatest median increase in
haemoglobin between infusion and surgery (15 mg/L,
range − 15 to 63), and the second highest median post-
operative day 1 haemoglobin (103 mg/L, range 87–138).
Those patients who were categorised as having an-
aemia of inflammation (ferritin ≥ 30 μg/L and CRP > 5
mg/L, n = 17) had a higher median pre-infusion haemo-
globin than either of the two iron-deficient groups (110
mg/L, range 75 to 117), a lower median increase in
haemoglobin between infusion and surgery than either
of the two iron-deficient groups (3 mg/L, range − 11 to
34), and a lower median postoperative day 1 haemoglo-
bin than either of the two iron-deficient groups (102
mg/L, range 74–113).
Finally, those patients who were categorised as having
anaemia of another cause or without evidence of iron
deficiency (ferritin < 30 μg/L and CRP ≤ 5 mg/L, n = 18)
had a similar median pre-infusion haemoglobin to those
with anaemia of inflammation (110 mg/L, range 103 to
115). They had a median decrease in haemoglobin be-
tween infusion and surgery (− 5 mg/L, range − 10 to 8)
and the lowest median postoperative day 1 haemoglobin
(95 mg/L, range 85 to 99). Although this group were not
defined as iron deficient by protocol, none were found
to be vitamin B12 or folate deficient.
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Associations with post-iron infusion change in
haemoglobin
At multivariate linear regression (Table 3), total paren-
teral iron dose (p = 0.034), time from infusion to surgery
(p < 0.001), haemoglobin prior to iron infusion (p =
0.002), and CRP- and ferritin-based iron status group (p
= 0.006) all remained independently associated with post
iron infusion change in haemoglobin.
Discussion
The results of the present study suggest that, in patients
with primary operable colorectal cancer found to be an-
aemic at diagnosis, preoperative iron infusions improved
pre- and postoperative haemoglobin in the truly iron
deficient, but not those without evidence of iron defi-
ciency. Those patients with low ferritin in the presence
of inflammation, consistent with the presence of func-
tional iron deficiency, had an intermediate haemoglobin
response to iron infusion. Those with both high ferritin
and high CRP, consistent with the presence of anaemia
of inflammation, had a negligible haemoglobin response
to iron infusion. In addition, a higher dose of iron, a
longer time delay between infusion and surgery, and a
lower haemoglobin before infusion were associated with
greater increases in haemoglobin after iron infusion.
These findings are in-keeping with the hypothesis that
in a proportion of anaemic colorectal cancer patients,
the host inflammatory response to cancer leads to either
a state of functional iron deficiency anaemia or anaemia
of inflammation (Tokunaga et al. 2018). It would appear
from this small cohort that functional iron deficiency
can, to an extent, be improved by parenteral iron supple-
mentation. It may be that in this group, the dose and
Table 1 Demographic and clinicopathological variables of
patients receiving intravenous iron infusions prior to elective








< 65 9 (17)
65–75 15 (29)













Right colon 38 (72)












Median (range) 18 (3–302)
< 30 36 (74)
30–100 7 (14)
> 100 6 (12)
Pre-infusion CRP (mg/L)
Median (range) 6 (1–113)
≤ 5 24 (50)
> 5 24 (50)
Table 1 Demographic and clinicopathological variables of
patients receiving intravenous iron infusions prior to elective
colorectal surgery for cancer (n = 52) (Continued)
Characteristic n (%)




Days from infusion to surgery
Median (range) 24 (1–83)
Haematological outcomes
Post-infusion change (Δ) in Hb (mg/L)




ASA American Society of Anesthesiology, CRP C-reactive protein, IV intravenous
*Pre-iron infusion haemoglobin: males < 130 mg/L, females < 120 mg/L
$Post-iron infusion haemoglobin: males ≥ 130 mg/L, females ≥ 120 mg/L
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Table 2 Clinicopathological and haematological factors associated with protocol-defined iron status prior to intravenous iron
infusion for elective colorectal surgery for cancer (n = 47)
Characteristic Pre-infusion iron status p
IDA
(CRP ≤ 5 + Fer < 30)
n (%)
FID
(CRP > 5 + Fer < 30)
n (%)
AOI
(CRP > 5 + Fer ≥ 30)
n (%)
Replete/other
(CRP ≤ 5 + Fer ≥ 30)
n (%)
Total 18 (38) 17 (38) 6 (12) 6 (12) –
Patient characteristics
Sex
Male 13 (72) 10 (59) 1 (17) 3 (50) 0.120
Female 5 (28) 7 (41) 5 (83) 3 (50)
Age (years)
< 65 1 (6) 5 (29) 1 (17) 1 (17) 0.261
65–75 6 (33) 2 (12) 3 (50) 3 (50)
> 75 11 (61) 10 (59) 2 (33) 2 (33)
ASA
1 0 (0) 2 (12) 0 (0) 0 (0) 0.070
2 9 (50) 3 (17) 6 (100) 4 (67)
3 8 (44) 11 (65) 0 (0) 2 (33)
4 1 (6) 1 (6) 0 (0) 0 (0)
Pathologic characteristics
TNM stage
1 1 (6) 3 (18) 0 (0) 2 (33) 0.448
2 11 (61) 5 (29) 3 (50) 3 (50)
3 6 (33) 8 (47) 3 (50) 1 (17)
4 0 (0) 1 (6) 0 (0) 0 (0)
Tumour site
Right colon 8 (44) 17 (100) 5 (83) 5 (83) 0.006
Left colon 3 (17) 0 (0) 1 (17) 1 (17)
Rectum 7 (39) 0 (0) 0 (0) 0 (0)
Infusion variables
Total IV iron dose (mg)
1000 7 (44) 6 (40) 0 (0) 3 (50) 0.254
1500 4 (25) 7 (47) 4 (67) 3 (50)
2000 5 (31) 2 (13) 2 (33) 0 (0)
Days from infusion
to surgery
Median (range) 20 (3–83) 30 (7–62) 25 (19–44) 16 (2–48) 0.233
Haematological variables
Pre-iron Hb (mg/L)
Median (range) 100 (77–118) 102 (65–122) 110 (75–117) 110 (103–115) 0.101
Δ Hb (mg/L)
Median (range) 24 (− 6 to 48) 15 (− 15 to 63) 3 (− 11 to 34) − 5 (− 10 to 8) 0.017
POD1 Hb (mg/L)
Median (range) 108 (87–133) 103 (87–138) 102 (74–113) 95 (85–99) 0.028
AOI anaemia of inflammation, ASA American Society of Anesthesiology, CRP C-reactive protein (mg/L), Fer ferritin (μg/L), FID functional iron deficiency, Hb
haemoglobin (g/L), IDA iron deficiency anaemia, IV intravenous, POD postoperative day
McSorley et al. Perioperative Medicine            (2020) 9:17 Page 6 of 9
parenteral route of iron supplementation overcomes
hepcidin-mediated iron sequestration and inhibition of
absorption of dietary iron; however, this does not fully ex-
plain the lesser response to iron seen in patients with high
levels of inflammation (Munoz et al. 2011). Although pre-
vious studies have noted success in the correction of pre-
operative anaemia with oral iron in true iron deficiency
(Lidder et al. 2007), it is less clear whether oral supple-
mentation is of use in the FID group.
Conversely, those patients with haematological and
biochemical measures consistent with anaemia of in-
flammation (normal ferritin, raised CRP) appear to have
anaemia which is resistant to correction by iron infusion
as it is likely caused by other factors. The prevalence of
this condition in colorectal cancer must be recognised
and clinicians should be cognoscente of this when deter-
mining how to optimise their patients in the periopera-
tive period. Preoperative systemic inflammation has
been reported to be associated with co-morbidity, post-
operative complications, and poorer long-term survival
in patients with colorectal cancer, and it may be that
preoperative anaemia is an important and related factor
(Dolan et al. 2018).
Allogeneic blood transfusions have been associated
with increased postoperative infective complications, in-
creased disease recurrence, and poorer survival following
surgery for colorectal cancer (Acheson et al. 2012; Pang
et al. 2019). Although the mechanism is not fully under-
stood, one key hypothesis is that allogenic blood causes
host adaptive immune suppression (Blumberg and Heal
1994), even when using modern leucodepleted packed
red cells (Mynster et al. 2000). Therefore, current trends
in perioperative medicine and blood management strat-
egies aim to reduce the need for perioperative allogeneic
blood transfusion, with preoperative iron supplementa-
tion forming a key strategy (Ng et al. 2015). Parenteral
iron is not without potential for harm, being associated
with a small risk of anaphylaxis. In addition, there is
now some evidence that excess iron may be associated
with negative oncologic outcomes (Xue et al. 2016;
Greten 2016; Radulescu et al. 2012). It is possible that
such an effect may be compounded in patients with an
existing host systemic inflammatory response, although
further studies are required to examine this matter. In
attempting to reduce perioperative transfusion, there is
evidence from this study, unsurprisingly, that the best
haemoglobin response to parenteral iron replacement is
in those with true iron deficiency. Further strategies pre-
venting and addressing other causes of anaemia in colo-
rectal cancer are required. This can only be achieved by
better understanding of the causes of anaemia in this pa-
tient group. It is possible that treatment of inflammation
may release checks on erythropoiesis and should be the
subject of further study.
It was of interest that tumour site appeared to have an
impact on pre-iron infusion iron status defined by CRP
and ferritin in this protocol. Almost all patients grouped
as having functional iron deficiency and anaemia of in-
flammation had right colonic lesions, as opposed to the
significant proportion of patients with rectal cancer in
the true iron-deficient group. The link between right
colonic tumours and the presence of both local and sys-
temic inflammation has been documented previously
(Patel et al. 2018), as has the association between right
colonic tumours and normocytic anaemia (Vayrynen
et al. 2018). Therefore, the host interaction with these
proximal colonic lesions seems to drive systemic inflam-
matory driven changes in iron and erythrocytes.
This study has a number of limitations. The number
of patients is small, increasing the risk of type 2 error.
No data was available regarding patients who had re-
ceived oral iron supplementation in either primary or
secondary care before diagnosis or surgery, increasing
the possibility of selection bias and preventing a useful
Table 3 Univariate and multivariate linear regression of factors associated with change in haemoglobin (Δ Hb mg/L) following






Male sex − 7.7 (− 17.3 to 1.9) 0.112 – –
Age 4.7 (− 1.6 to 10.9) 0.140 – –
ASA 2.0 (− 5.6 to 9.7) 0.594 – –
TNM stage 8.2 (2.2–14.2) 0.008 – 0.780
Tumour site 1.8 (− 4.9 to 8.6) 0.590 – –
Total iron dose (mg) 0.02 (0.01–0.03) 0.003 0.01 (0.0–0.2) 0.034
Days from infusion to surgery 0.5 (0.3–0.7) < 0.001 0.4 (0.2–0.6) < 0.001
Pre-iron infusion Hb (mg/L) − 0.8 (− 1.1 to − 0.6) < 0.001 − 0.5 (− 0.7 to − 0.2) 0.002
Pre-iron infusion CRP and ferritin group − 6.9 (− 11.50 to − 2.19) 0.005 − 4.7 (− 7.9 to − 1.47) 0.006
AOI anaemia of inflammation, ASA American Society of Anesthesiology, CRP C-reactive protein (mg/L), Fer ferritin (μg/L), FID functional iron deficiency, Hb
haemoglobin (g/L), IDA iron deficiency anaemia, IV intravenous, POD postoperative day
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comparison between different routes of iron supplemen-
tation in patients with functional iron deficiency or an-
aemia of inflammation. Furthermore, there were no data
examining patients with functional iron deficiency or an-
aemia of inflammation who did not receive a preopera-
tive iron infusion. In addition, a number of patients who
were anaemic but without evidence of inflammation or
iron deficiency received an iron infusion, against the unit
protocol. Again, this could suggest selection bias, but in
terms of an observational study, provided an additional
interesting group of patients for comparison in a real-
world study, with findings confirming they fail to re-
spond to iron infusion as hypothesised. Although data
did exist relating to perioperative blood transfusion in this
cohort, the lack of an established transfusion protocol
meant that this was not included in the analysis. Finally,
there was no reliable recording of estimated operative
blood loss in the cohort, which may lead to bias with re-
gard to the analysis of postoperative haemoglobin.
In summary, this observational study reports a reduced
efficacy of preoperative parenteral iron supplementation
in patients thought to have anaemia of inflammation, and
to a lesser extent functional iron deficiency, in patients
undergoing surgery for colorectal cancer, compared with
those who were truly iron deficient. This study illustrates
that iron infusion is of greatest benefit to the truly iron-
deficient patient in the absence of preoperative inflamma-
tion. Given that the presence of anaemia and inflamma-
tion are in fact much more common in the preoperative
colorectal cancer population than iron deficiency anaemia
alone, these results suggest that this area requires further
focused study. It may be that alternative preoperative
haemoglobin optimisation methods, for example targeting
the underlying host inflammatory response to cancer, may
prove to be of more use in these groups of patients than
targeting all patients with low ferritin levels with preopera-
tive iron infusions.
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